Unbiased Analysis of Today's Healthcare Issues
Last week, CMS announced the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model. The program basically is a ‘most favored nation’ style reference pricing based on net prices from developed countries. The program builds on the Medicaid Drug Rebate Program (MDRP). Specific details specified on the CMS website include: Participating manufacturers whose applications are accepted…
On July 31, President Trump sent letters to some of the largest pharmaceutical companies in the world (AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi) asking them to fundamentally change drug pricing in the US. What was…
That is the topic of a JMCP Viewpoint by Sean Sullivan, Jens Grueger, Aidan Sullivan, and Scott Ramsey. Some excerpts: The Budget Lab at Yale University projected that a 25% ad valorem tariff would increase medication costs by an “average of around $600 per year per household in the United States.”3 Tariffs can also create supply…
In a statement today, CMS confirmed that Elon Musk and the Department of Government Efficiency (DOGE) has been given access to CMS payment systems: CMS has two senior Agency veterans – one focused on policy and one focused on operations – who are leading the collaboration with DOGE, including ensuring appropriate access to CMS systems…
Some hints–and only hints–were provided in a CMS press release on Wednesday. Lowering the cost of prescription drugs for Americans is a top priority of President Trump and his Administration. In accordance with the statutory requirements of the Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) released the list of 15 drugs…
How has President Trump’s recent executive orders reshaped the US healthcare system? Below, I summarize the healthcare-related Executive Orders that were released this week: ACA premium subsidies will be reduced: Trump rescinded Biden’s executive order that led to longer enrollment periods for Affordable Care Act plans in most states. In short, in 2021, temporary subsidies…
The Washington Post reports on a meeting between President-elect Trump, Robert F. Kennedy, Jr. and a number of CEOs of pharmaceutical firms. When the topic turned to vaccines, the discussion was not about banning the products, the three people said. Kennedy spoke about the need for better study of the vaccine dosing schedule for newborns…
President Trump signed 4 executive orders on drug pricing on July 24, 2020. How are they likely to affect drugs prices? Passing along rebates to patients The one of the executive orders mandates that rebates go to reduce patient cost sharing: These middlemen — health plan sponsors and pharmacy benefit managers (PBMs) — negotiate significant…
As of January 30, 2020, President Trump has an overall approval rating of 42.8% according to 538. He has a disapproval rating of 52.8% leading to a net rating of -10% Yet this overall number may hide heterogeneity in what people think. Maybe public opinion of President Trump is more favorable on some issues than…
President Trump wants to allow more people be able to purchase lower cost health plans. Most of the media has focused on plans to make it easier to purchase short-term plans and association health plans. However, a recent final rule is also making it easier to use pre-tax dollars to fund premiums for individual health…